Evidence map›Paper›PMID 27029813›Full record

ArticleBMC genomics2016

Multivariate models from RNA-Seq SNVs yield candidate molecular targets for biomarker discovery: SNV-DA.

Matt R Paul, Nicholas P Levitt, David E Moore, Patricia M Watson, Robert C Wilson, Chadrick E Denlinger, Dennis K Watson, Paul E Anderson

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Single nucleotide variant counts computed from RNA sequencing and cellular traffic into human kidney allografts.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2018
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Matt R PaulDepartment of Computer Science, College of Charleston, 66 George St., Charleston, SC, USA. mattpaul@mail.med.upenn.edu.
Nicholas P LevittDepartment of Computer Science, College of Charleston, 66 George St., Charleston, SC, USA.
David E MooreDepartment of Computer Science, College of Charleston, 66 George St., Charleston, SC, USA.
Patricia M WatsonHollings Cancer Center, Medical University of South Carolina, 165 Canon St., Charleston, SC, USA.
Robert C WilsonHollings Cancer Center, Medical University of South Carolina, 165 Canon St., Charleston, SC, USA.
Chadrick E DenlingerDepartment of Pathology, Medical University of South Carolina, 165 Canon St., Charleston, SC, USA.
Dennis K WatsonHollings Cancer Center, Medical University of South Carolina, 165 Canon St., Charleston, SC, USA.
Paul E AndersonDepartment of Computer Science, College of Charleston, 66 George St., Charleston, SC, USA.
College of Charleston · USMedical University of South Carolina · USMUSC Hollings Cancer Center · US

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI John J Lemasters · 2009 to 2026
$42.7M
NCI NIH HHS P30 CA 138313NCI NIH HHS P30 CA138313
6 · The paper itself

Abstract

backgroundIt has recently been shown that significant and accurate single nucleotide variants (SNVs) can be reliably called from RNA-Seq data. These may provide another source of features for multivariate predictive modeling of disease phenotype for the prioritization of candidate biomarkers. The continuous nature of SNV allele fraction features allows the concurrent investigation of several genomic phenomena, including allele specific expression, clonal expansion and/or deletion, and copy number variation.

resultsThe proposed software pipeline and package, SNV Discriminant Analysis (SNV-DA), was applied on two RNA-Seq datasets with varying sample sizes sequenced at different depths: a dataset containing primary tumors from twenty patients with different disease outcomes in lung adenocarcinoma and a larger dataset of primary tumors representing two major breast cancer subtypes, estrogen receptor positive and triple negative. Predictive models were generated using the machine learning algorithm, sparse projections to latent structures discriminant analysis. Training sets composed of RNA-Seq SNV features limited to genomic regions of origin (e.g. exonic or intronic) and/or RNA-editing sites were shown to produce models with accurate predictive performances, were discriminant towards true label groupings, and were able to produce SNV rankings significantly different from than univariate tests. Furthermore, the utility of the proposed methodology is supported by its comparable performance to traditional models as well as the enrichment of selected SNVs located in genes previously associated with cancer and genes showing allele-specific expression. As proof of concept, we highlight the discovery of a previously unannotated intergenic locus that is associated with epigenetic regulatory marks in cancer and whose significant allele-specific expression is correlated with ER+ status; hereafter named ER+ associated hotspot (ERPAHS).

conclusionThe use of models from RNA-Seq SNVs to identify and prioritize candidate molecular targets for biomarker discovery is supported by the ability of the proposed method to produce significantly accurate predictive models that are discriminant towards true label groupings. Importantly, the proposed methodology allows investigation of mutations outside of exonic regions and identification of interesting expressed loci not included in traditional gene annotations. An implementation of the proposed methodology is provided that allows the user to specify SNV filtering criteria and cross-validation design during model creation and evaluation.

Indexed as

Models, GeneticPolymorphism, Single NucleotideSequence Analysis, RNASoftware3' Untranslated RegionsAdenocarcinomaAdenocarcinoma of LungAlgorithmsBiomarkers, TumorBreast NeoplasmsCarcinoma, Non-Small-Cell LungDiscriminant AnalysisDNA, IntergenicExonsFemaleHumans3' Untranslated RegionsBiomarkers, TumorDNA, IntergenicBiomarker discoveryER+ERPAHSMultivariate modelsNSCLCSNVsPLS-DATNBC

Identifiers

PMID27029813
PMCPMC4815211
OpenAlexW2333086536

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.